Skip to main content
CAPR
NASDAQ Life Sciences

Capricor Surges as 24-Month Deramiocel Data Show Durable Benefit in Duchenne

Tom Rudovsky · Reported by Seeking Alpha
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.27
Mkt Cap
$498.251M
52W Low
$2.96
52W High
$40.37
52W Position info
247% above low
Off High info
75% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CAPR has more than doubled off its 52-week low of $2.96.

Summary

Capricor shares jumped in late trading after new 24-month data on deramiocel were presented in a late-breaking poster at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan. In the open-label extension, placebo crossover patients' upper limb decline slowed 76% in their first year on deramiocel, with a least-squares mean change of −0.49 in Year 2 versus −2.05 in Year 1, while the early-start deramiocel arm showed changes of −0.89 and −0.95, respectively. Both groups declined slower than natural history at 24 months, with observed changes of −3.76 and −3.42 versus predicted changes of −5.35 and −5.88. The analyses include a delayed-start comparison and natural history benchmark, with 82 of 106 HOPE-3 patients reaching 24 months. The data are part of the BLA amendment already under FDA review, with a PDUFA date of November 22. This follows the FDA advisory committee's 9-3 negative vote on cardiomyopathy effectiveness in July, but the new longer-term upper-limb data may strengthen the overall benefit-risk case. An oral presentation by Craig McDonald on October 3 will provide further detail on skeletal-muscle and cardiac effects.

Updated with a GlobeNewswire report · What changed

Updates

  1. · GlobeNewswire — Placebo crossover patients' upper limb decline slowed 76% in their first year on deramiocel; both groups declined slower than natural history at 24 months.

    • Upper Limb Decline — Placebo arm Year 1 LS mean change on placebo was −2.05 (n=52) and Year 2 on Deramiocel was −0.49 (n=49), a difference of 1.56 (95% CI: 0.47 to 2.64). Deramiocel arm Year 1 LS mean change was −0.95 (n=54) and Year 2 was −0.89 (n=49), a difference of 0.05 (95% CI: −1.03 to 1.14).
    • Natural History Comparison
      • Placebo arm (12 months on Deramiocel) observed Month 24 change was −3.76.
      • Placebo arm (12 months on Deramiocel) predicted by natural history Month 24 change was −5.35.
      • Deramiocel arm (24 months on Deramiocel) observed Month 24 change was −3.42.
      • Deramiocel arm (24 months on Deramiocel) predicted by natural history Month 24 change was −5.88.
      • The natural history model used was Michaëls 2025 and Niks 2026.
      • In its untreated year, the Placebo arm tracked the model (−2.7 observed vs −2.9 predicted at Month 12).
      • The natural history comparison was descriptive only; no matching or statistical testing.
      • Slower decline in patients on Deramiocel was triggered by starting treatment, not passage of time.
      • Natural history model (Michaëls 2025; Niks 2026) predicts each patient’s decline from baseline score, age and ambulatory status.
      • Placebo arm's untreated year tracked a published non-ambulant cohort (about −2.7 points per year; Coratti 2025).
    • Trial Design
      • 98 patients entered the open-label extension (49 per arm).
      • Patients assessed at Month 24 were 42 in placebo arm and 40 in Deramiocel arm.
      • No alpha was allocated to these open-label analyses, and the extension was not powered for Month 24 comparisons.
      • Least-squares mean change from a mixed model for repeated measures, adjusted for starting score, cohort, site and slow-progressor status.
      • The BLA amendment included extensive sensitivity and robustness analyses.
      • Deramiocel was administered intravenously every three months over a 12-month treatment period in the randomized phase.
      • Least-squares mean change from a mixed model for repeated measures, with each year measured from its own starting point (Day 0 or Month 12) and adjusted for starting score, cohort, site and slow-progressor status.
      • HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial.
      • Upper limb function is measured by PUL 2.0 Total Score.
    • Presentation — The 24-month data were presented in a late-breaking poster at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan.
    All 27 details
    • Placebo arm (delayed start) Year 1 LS mean change on placebo was −2.05 (n=52).
    • Placebo arm (delayed start) Year 2 LS mean change on Deramiocel was −0.49 (n=49).
    • Difference in decline rate for placebo arm, Year 2 vs Year 1, was 1.56 (95% CI: 0.47 to 2.64).
    • Deramiocel arm (early start) Year 1 LS mean change on Deramiocel was −0.95 (n=54).
    • Deramiocel arm (early start) Year 2 LS mean change on Deramiocel was −0.89 (n=49).
    • Difference in decline rate for Deramiocel arm, Year 2 vs Year 1, was 0.05 (95% CI: −1.03 to 1.14).
    • Placebo arm (12 months on Deramiocel) observed Month 24 change was −3.76.
    • Placebo arm (12 months on Deramiocel) predicted by natural history Month 24 change was −5.35.
    • Deramiocel arm (24 months on Deramiocel) observed Month 24 change was −3.42.
    • Deramiocel arm (24 months on Deramiocel) predicted by natural history Month 24 change was −5.88.
    • 98 patients entered the open-label extension (49 per arm).
    • Patients assessed at Month 24 were 42 in placebo arm and 40 in Deramiocel arm.
    • The 24-month data were presented in a late-breaking poster presentation at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan.
    • No alpha was allocated to these open-label analyses, and the extension was not powered for Month 24 comparisons.
    • Least-squares mean change from a mixed model for repeated measures, adjusted for starting score, cohort, site and slow-progressor status.
    • The natural history model used was Michaëls 2025 and Niks 2026.
    • In its untreated year, the Placebo arm tracked the model (−2.7 observed vs −2.9 predicted at Month 12).
    • The natural history comparison was descriptive only; no matching or statistical testing.
    • Slower decline in patients on Deramiocel was triggered by starting treatment, not passage of time.
    • The BLA amendment included extensive sensitivity and robustness analyses.
    • Deramiocel was administered intravenously every three months over a 12-month treatment period in the randomized phase.
    • Least-squares mean change from a mixed model for repeated measures, with each year measured from its own starting point (Day 0 or Month 12) and adjusted for starting score, cohort, site and slow-progressor status.
    • Natural history model (Michaëls 2025; Niks 2026) predicts each patient’s decline from baseline score, age and ambulatory status.
    • Placebo arm's untreated year tracked a published non-ambulant cohort (about −2.7 points per year; Coratti 2025).
    • HOPE-3 is a Phase 3, randomized, double-blind, placebo-controlled trial.
    • Upper limb function is measured by PUL 2.0 Total Score.
    • Deramiocel is also known as CAP-1002.

At the time of this announcement, CAPR was trading at $10.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $498.3M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.


Price Chart

Share this article

Copied!

CAPR - Latest Insights

CAPR
Nov 10, 2026, 5:25 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.35
Real-time Price: $9.26 info
Change: -$0.090 (-0.96%) info
Market Cap: $515.693M info
CAPR
Nov 10, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $9.10
Real-time Price: $9.26 info
Change: +$0.160 (+2%) info
Market Cap: $515.693M info
CAPR
Nov 10, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $9.26 info
Change: +$0.355 (+4%) info
Market Cap: $515.693M info
CAPR
Nov 09, 2026, 9:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $9.08
Real-time Price: $9.26 info
Change: +$0.177 (+2%) info
Market Cap: $515.693M info
CAPR
Oct 05, 2026, 12:12 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $8.22
Real-time Price: $9.26 info
Change: +$1.04 (+13%) info
Market Cap: $515.693M info